<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117387</url>
  </required_header>
  <id_info>
    <org_study_id>P17.050</org_study_id>
    <nct_id>NCT03117387</nct_id>
  </id_info>
  <brief_title>Evaluation of the TOF CUFF for Perioperative Neuromuscular Transmission</brief_title>
  <official_title>Evaluation of the TOF CUFF for Perioperative Neuromuscular Transmission Monitoring During Recovery of Moderate and Deep Neuromuscular Block Compared to Acceleromyography and Electromyography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acceleromyography (AMG) is the most wide spread used method to assess neuromuscular block
      during anesthesia. However AMG is known to be inaccurate when compared to the gold standard
      in neuromuscular transmission monitoring, electromyography (EMG). Furthermore when the
      patients arms require to be positioned next to the body and beneath surgical drapes, AMG
      measurements are often hindered and inaccurate. The TOF cuff is a new device which measures
      NMB at the upper arm with a blood pressure cuff. It overcomes the previously mentioned
      disadvantages of AMG. However, it validity compared to EMG and AMG has not yet fully been
      investigated.

      This study aims to compare the bias, limits of agreement and precision of the TOF cuff
      relative to AMG and EMG during recovery of moderate and deep neuromuscular block in patients
      with normal body mass index and morbidly obese patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">January 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Depth of neuromuscular block as measured by a train of four ratio or post tetanic count will be compared between the three devices by bland altman analysis</measure>
    <time_frame>intraoperative</time_frame>
    <description>During anesthesia, depth of neuromuscular block will be assessed at regular intervals</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>moderate neuromuscular block, normal body mass index</arm_group_label>
    <description>Patients with normal BMI (&lt; 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>deep neuromuscular block, normal body mass index</arm_group_label>
    <description>Patients with normal BMI (&lt; 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate neuromuscular block, high body mass index</arm_group_label>
    <description>Patients with high BMI (&gt; 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>deep neuromuscular block, high body mass index</arm_group_label>
    <description>Patients with high BMI (&gt; 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>This study contains no interventions</description>
    <arm_group_label>deep neuromuscular block, high body mass index</arm_group_label>
    <arm_group_label>deep neuromuscular block, normal body mass index</arm_group_label>
    <arm_group_label>moderate neuromuscular block, high body mass index</arm_group_label>
    <arm_group_label>moderate neuromuscular block, normal body mass index</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ASA I-III patients &gt;18 years of age BMI either &lt; 30 or &gt; 30 kg/m2
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I-III

          -  &gt;18 years of age

          -  Ability to give oral and written informed consent

        Exclusion Criteria:

          -  Known or suspected neuromuscular disorders impairing neuromuscular function;

          -  Allergies to muscle relaxants, anesthetics or narcotics;

          -  A (family) history of malignant hyperthermia;

          -  Women who are or may be pregnant or are currently breast feeding;

          -  Renal insufficiency, as defined by a glomerular filtration rate &lt; 30 ml/min

          -  Scheduled for anesthesia without the use of muscle relaxants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Dahan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert Dahan, MD PhD</last_name>
    <phone>+31 71 52 62301</phone>
    <email>a.dahan@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden / Nederlandse Obesitas Kliniek</name>
      <address>
        <city>The Hague</city>
        <state>Zuid Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Torensma, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Dahan, &lt;D</last_name>
      <phone>+31 71 52 62301</phone>
      <email>a.dahan@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>A. Dahan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Albert Dahan</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

